证券代码：873167 证券简称：新赣江 公告编号：2024-014 江西新赣江药业股份有限公司 第二届董事会第二十九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 1 日 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯 4.发出董事会会议通知的时间和方式：2024 年 3 月 19 日以书面方式发出 5.会议主持人：董事长张爱江先生 6.会议列席人员：公司高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议召集、召开、议案审议程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 二、议案审议情况 （一）审议通过《关于公司<2023 年年度报告及摘要>的议案》 1.议案内容： 根据《公开发行证券的公司信息披露内容与格式准则第 53 号——北京证 券交易所上市公司年度报告》《北京证券交易所股票 ...

证券代码：873167 证券简称：新赣江 公告编号：2024-032 江西新赣江药业股份有限公司 关于拟注销两家三级子公司的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、 准确性和完整性承担个别及连带法律责任。 一、基本情况 为进一步优化资源配置，降低管理成本，江西新赣江药业股份有 限公司（以下简称"公司"）拟注销孙公司江西奥匹神药业有限公司 （以下简称"奥匹神药业"）的子公司江西奥匹神医疗管理有限公司 和江西聚优云酷医药咨询有限公司，并委托公司相关部门人员于近期 办理注销手续。拟注销公司基本情况如下： 公司名称 1：江西奥匹神医疗管理有限公司 企业类型：有限责任公司(自然人投资或控股的法人独资) 注册地址：江西省南昌市红谷滩区九龙大道 1177 号绿地国际博 览城 JLH605-B01 地块 101#商业办公室 1109 室 法定代表人：罗来兵 成立日期：2021 年 1 月 22 日 经营范围：医院管理，企业管理，健康咨询服务（不含诊疗服务）， 中医养生保健服务（非医疗），信息咨询服务（不含许可类信息咨询 注册地址：江西省南昌市红谷 ...

Company Recognition and Certifications - The company was awarded the "Jiangxi Famous Brand Product" for its Vitamin C Chewable Tablets in June 2023[3]. - The company’s subsidiary, Jiangxi Zhongyuan Pharmaceutical Co., Ltd., received the "High-tech Enterprise Certificate" from multiple government bodies in November 2023[3]. - The company has been recognized as a "High-tech Enterprise" and has achieved provincial-level recognition for its specialized and innovative capabilities[44]. Financial Performance - The company's total revenue for 2023 was approximately ¥216.48 million, representing a year-over-year increase of 2.53% compared to ¥211.15 million in 2022[25]. - The net profit attributable to shareholders decreased by 1.63% to ¥45.57 million in 2023 from ¥46.32 million in 2022[25]. - The gross profit margin improved to 47.15% in 2023, up from 46.07% in 2022[25]. - Total assets increased by 47.49% to ¥521.93 million at the end of 2023, compared to ¥353.88 million at the end of 2022[27]. - The company's total liabilities decreased by 32.28% to ¥48.21 million in 2023 from ¥71.19 million in 2022[27]. - The net asset attributable to shareholders rose by 68.97% to ¥470.58 million in 2023, compared to ¥278.50 million in 2022[27]. - The basic earnings per share fell by 24.44% to ¥0.68 in 2023 from ¥0.90 in 2022[25]. - The cash flow from operating activities was ¥40.43 million in 2023, down from ¥89.42 million in 2022[27]. - The company reported a non-recurring profit and loss of approximately ¥9.41 million in 2023, compared to ¥1.15 million in 2022[33]. Shareholder and Stock Information - The total share capital of the company is 70,861,250 shares[17]. - The company issued 19,636,250 shares in a public offering on February 9, 2023, with 3,415,000 shares subject to a 6-month lock-up period[138]. - As of December 31, 2023, the controlling shareholder, Zhang Aijiang, holds 49.19% of the company's shares directly and an additional 7.01% indirectly through Kaida Consulting, totaling 56.20%[145]. - The actual controllers, including Zhang Aijiang, Zhang Ming, Zhang Jia, Zhang Mi, and Yan Qipeng, collectively hold 70.86% of the company's shares[146]. - The total number of ordinary shareholders is 3,896[137]. Regulatory Compliance and Industry Standards - The company operates under strict industry regulations, including drug production licenses and quality management systems, as mandated by the 2019 revised Drug Administration Law[54]. - The company adheres to the national drug standards set by the State Drug Administration, ensuring compliance with the Pharmacopoeia of the People's Republic of China[55]. - The company is required to conduct consistency evaluations for generic drugs to ensure they match the quality and efficacy of original drugs, as per national guidelines[59]. - The company is subject to a series of legal regulations, including the Drug Administration Law and various management measures, to ensure drug safety and quality[60]. Research and Development - R&D expenditure amounted to ¥10,028,631.66, representing 4.63% of operating income, an increase from 4.20% in the previous period[100][99]. - The number of patents owned by the company increased to 67 from 53, with the number of invention patents rising to 9 from 8[102]. - The company has completed clinical trials for the new drug Succinic Acid Doxylamine, aiming to enhance product quality and market competitiveness[104]. - The company is conducting research to improve the quality of Gluconate Calcium and Gluconate Zinc, which will enhance product quality and profitability[104]. - The company is actively expanding its product portfolio through new drug development and technological advancements[199]. Market Strategy and Sales - The company employs a mixed sales strategy of distribution and direct sales for its chemical drug formulations and traditional Chinese medicine products[41]. - The sales model for chemical raw materials primarily involves direct sales to downstream formulation manufacturers, establishing long-term partnerships with key clients[40]. - The company aims to strengthen its sales team and optimize its sales system to promote sustainable growth in its main business[117]. - The company has established long-term partnerships with major clients in the industry, ensuring stable sales channels for its raw materials[195]. Environmental and Quality Management - The company is committed to adhering to strict quality, environmental, and health standards as part of its operational strategy[179]. - The company has established an environmental protection and safety production team to ensure compliance with national regulations[120]. - The company is actively exploring energy-saving and emission-reduction technologies in its production processes[120]. Future Outlook and Growth Plans - The company plans to continue optimizing its product sales structure and enhancing brand influence to support future growth[46]. - The company aims to enhance its internationalization level and modernize its industrial chain by 2035, as outlined in the national pharmaceutical development plan[71]. - The company plans to increase R&D investment and market promotion to enhance brand recognition and establish a comprehensive health ecosystem in 2024[116]. - The company has set a future outlook with a revenue target of 1.5 billion CNY for the next fiscal year, indicating a projected growth of 25%[185].

证券代码：873167 证券简称：新赣江 公告编号：2024-011 江西新赣江药业股份有限公司 为全资子公司提供担保的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、担保情况概述 （一）担保基本情况 江西新赣江药业股份有限公司（以下简称"公司"或"新赣江"）全资子公 司江西众源药业有限公司（以下简称"众源药业"）为 2023 年度江西省重点创新 产业化升级工程项目被扶持单位，受扶持项目为中药制剂保健品生产。江西国资 创业投资管理有限公司为重点创新产业化升级工程受托管理执行机构，以提供借 款的方式向众源药业提供扶持资金 2,000 万元，期限为三年，到期归还本金。 公司、控股股东张爱江及其配偶张燕娥共同为众源药业提供连带责任保证担 保，同时公司以所持众源药业约 45.87%股权（对应出资额 5000 万元）提供质押 担保，担保总额为 2,000 万元。 （二）是否构成关联交易 公司为全资子公司众源药业提供担保不构成关联交易。 （三）决策与审议程序 2024 年 3 月 21 日，公司第二届董事 ...

财通证券股份有限公司 关于江西新赣江药业股份有限公司 为全资子公司提供担保的核查意见 财通证券股份有限公司（以下简称"财通证券"或"保荐机构"）作为江西 新赣江药业股份有限公司（以下简称"新赣江"或"公司"）向不特定合格投资 者公开发行股票并在北京证券交易所上市的保荐机构，对新赣江履行持续督导义 务，根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则（试 行）》《北京证券交易所上市公司持续监管办法（试行）》《北京证券交易所证 券发行上市保荐业务管理细则》等相关法律、法规和规范性文件的规定，对新赣 江为全资子公司提供担保的事项进行了审慎核查，具体核查情况如下： 注册资本：10,900 万元 实缴资本：10,900 万元 企业类型：有限责任公司（控股的法人独资） 法定代表人（如适用）：张佳 一、本次担保概述 公司全资子公司江西众源药业有限公司（以下简称"众源药业"）为 2023 年 度江西省重点创新产业化升级工程项目被扶持单位，受扶持项目为中药制剂保健 品生产。江西国资创业投资管理有限公司为重点创新产业化升级工程受托管理执 行机构，以提供借款的方式向众源药业提供扶持资金 2,000 万元，期限为三年 ...

证券代码：873167 证券简称：新赣江 公告编号：2024-012 江西新赣江药业股份有限公司 第二届董事会第二十八次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 3 月 21 日 7.召开情况合法、合规、合章程性说明： 本次会议召集、召开、议案审议程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 二、议案审议情况 （一）审议通过《为全资子公司提供担保的议案》 1.议案内容： 江西新赣江药业股份有限公司（以下简称"公司"）全资子公司江西众源药 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯 4.发出董事会会议通知的时间和方式：2024 年 3 月 11 日以书面方式发出 5.会议主持人：董事长张爱江先生 6.会议列席人员：公司高级管理人员 4.提交股东大会表决情况： 本议案无需提交股东大会审议。 三、备 ...

Financial Performance - The company's operating revenue for 2023 is CNY 216,752,768.24, representing a year-on-year increase of 2.65%[3] - Net profit attributable to shareholders of the listed company is CNY 46,226,503.04, a slight decrease of 0.21% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 38,412,269.43, down 15.27% year-on-year[3] - Basic earnings per share decreased by 23.33% to CNY 0.69[3] Assets and Equity - Total assets at the end of the reporting period reached CNY 519,274,003.48, an increase of 46.74% year-on-year[4] - Shareholders' equity attributable to the listed company increased by 69.21% to CNY 471,245,866.67[4] - The company's net asset per share rose by 22.24% to CNY 6.65[4] Share Capital - The number of shares increased from 51,225,000 to 70,861,250, raising CNY 185,562,562.50 through public offering[5] Impairment and Losses - The decline in net profit after deducting non-recurring gains is primarily due to increased impairment losses on long-term equity investments and losses from newly established subsidiaries[6] Cautionary Note - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[8]

| | 公告日期 2024-02-06 异常期间 | 无 | | | | --- | --- | --- | --- | --- | | | 成交数量 新赣江(873167) 连续竞价 （股） | 5475045 | 成交金额（万 元） | 6577.25 | | | 涉及事项 当日收盘价涨幅达到20%的前5只股票 | | | | | 买/卖 | 营业部或交易单元名称 | | 买入金额（元） | 卖出金额（元） | | 买1 | 机构专用 | | 6280766.33 | 2586000 | | 买2 | 甬兴证券有限公司宁波和源路证券营业部 | | 3906502.11 | 0 | | 买3 | 光大证券股份有限公司沈阳十一纬路营业部 | | 2982882.36 | 0 | | 买4 | 华泰证券股份有限公司沈阳大西路证券营业部 | | 1049670.33 | 0 | | 买5 | 海通证券股份有限公司长沙五一大道营业部 | | 939804.69 | 2296 | | 卖1 | 南京证券股份有限公司杭州新塘路证券营业部 | | 0 | 3316063.75 | | 卖2 | 机构专用 | | 6280 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-02- | | | | | 异常期间涨跌幅偏离值累计 | | 06 | 833454 | 同心传动 | 40358281.0 | 46105.5 | 达到63.58% | | 2024-02- | 837663 | 明阳科技 | 18864500.0 | 24413.58 | 异常期间涨跌幅偏离值累计 | | 06 | | | | | 达到51.32% | | 2024-02- | 873570 | 坤博精工 | 2748272 | 11043.36 | 当日收盘价涨幅达到30.00% | | 06 | | | | | | | 2024-02- | | 九菱科技 | | | 当日收盘价涨幅达到29.99% | | 06 | 873305 | | 3389123 | 5593.54 | | | 2024-02- | 833454 | 同心传动 | 22575674.0 | 29572.71 | 当日收盘价涨幅达到29.97% | | ...

证券代码：873167 证券简称：新赣江 公告编号：2024-008 江西新赣江药业股份有限公司（以下简称"公司"）全资子公司江西众源药 业有限公司（以下简称"众源药业"或"子公司"）于近日收到由江西省科学技 术厅、江西省财政厅、国家税务总局江西省税务局联合颁发的《高新技术企业证 书》，证书编号：GR202336001426，发证时间：2023 年 11 月 22 日，有效期：三 年。 江西新赣江药业股份有限公司 二、对公司的影响 根据《中华人民共和国企业所得税法》等相关规定，众源药业自获得高新技 术企业认定后的三年内享受高新技术企业税收优惠，企业所得税按 15%的税率缴 纳。高新技术企业的认定，是对公司及子公司在产业关键领域的重要性、先进性 以及技术水平、行业地位等的认可，是公司综合实力的体现，有利于提升核心竞 争力及品牌影响力，对公司经营发展具有积极作用。 三、备查文件 《高新技术企业证书》（证书编号：GR202336001426） 关于全资子公司被认定为高新技术企业的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 ...